Immunomod

ImmunoMod is a privately held biopharmaceutical company developing and commercializing innovative therapies for the prevention and cure of diabetes and related metabolic disorders. Our platform utilizes immune-modulating molecules as prophylactics, by leveraging their ability to attenuate inflammatory destruction. Developing an effective therapeutic to protect beta cell function in early onset Type I diabetics is our first priority and the efficacy of our lead drug candidate IM-ASN to preserve these cells has been evidenced in animal and compassionate human studies.

Learn more...

Learn more about our products

ImmunoMod was established with the vision of alleviating suffering caused by diabetes and related autoimmune diseases. ImmunoMod is dedicated to developing and commercializing proactive therapies which will treat, prevent and ultimately cure diabetes.